+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Combined stent insertion and single high-dose brachytherapy in patients with advanced esophageal cancer--results of a prospective safety study



Combined stent insertion and single high-dose brachytherapy in patients with advanced esophageal cancer--results of a prospective safety study



Diseases of the Esophagus 25(5): 410-415



Previous randomized studies comparing the two commonly used palliative treatments for incurable esophageal cancer, i.e. stent insertion and intraluminal brachytherapy, have revealed the pros and cons of each therapy. While stent treatment offers a more prompt effect, brachytherapy results in more long-lasting relief of dysphagia and a better health-related quality of life (HRQL) in those living longer. This prospective pilot study aimed to explore the feasibility and safety of combining these two regimes and incorporating a single high dose of internal radiation. Patients with newly diagnosed, incurable cancer of the esophagus and dysphagia were eligible for inclusion, and stent insertion followed by a single dose (12 Gy) of brachytherapy was performed as a two-stage procedure. Clinical parameters including HRQL and adverse events were registered at inclusion, and 1, 2, 3, 6, and 12 months later. Twelve patients (nine males) with a median age of 73 years (range 54-85) were included. Stent insertion followed by a single dose of brachytherapy was successfully performed in all but one patient who was treated with stent only. Relief of dysphagia was achieved in the majority of cases (10/11, P < 0.05), but HRQL did not improve except for dysphagia-related items. Only minor adverse events, including chest pain, reflux, and restenosis, were reported. The median survival time after inclusion was 6.6 months. Our conclusion is that the combination of stent insertion and single high-dose brachytherapy seems to be a feasible and safe palliative regime in patients with advanced esophageal cancer. Randomized trials comparing the efficacy of this strategy to stent insertion or brachytherapy alone are warranted.

(PDF emailed within 0-6 h: $19.90)

Accession: 052181099

Download citation: RISBibTeXText

PMID: 21899654

DOI: 10.1111/j.1442-2050.2011.01248.x


Related references

Combined palliative treatment by high-dose-rate brachytherapy, stent placement and laser therapy in patients with esophageal cancer. BrachyTherapy 6(2): 116-0, 2007

Randomized prospective study comparing high dose rate intraluminal brachytherapy alone to HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. International Journal of Radiation Oncology Biology Physics 57(2 Supplement): S218-S219, 2003

Randomized prospective study comparing high-dose-rate intraluminal brachytherapy (HDRILBT) alone with HDRILBT and external beam radiotherapy in the palliation of advanced esophageal cancer. BrachyTherapy 3(4): 191-195, 2004

Combination of biodegradable stent placement and single-dose brachytherapy is associated with an unacceptably high complication rate in the treatment of dysphagia from esophageal cancer. Gastrointestinal Endoscopy 76(2): 267-274, 2012

Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Diseases of the Esophagus 18(3): 131-139, 2005

High-dose-rate brachytherapy in treatment of non-melanoma skin cancer of head and neck region: preliminary results of a prospective single institution study. Journal of Contemporary BrachyTherapy 10(2): 115-122, 2018

High-dose-rate intraluminal brachytherapy prior to external radiochemotherapy in locally advanced esophageal cancer: preliminary results. Journal of Contemporary BrachyTherapy 9(1): 30-35, 2017

High dose rate brachytherapy for advanced thoracic esophageal cancer in patients ineligibles for chemoradiotherapy. Radiotherapy & Oncology 56(Supplement 1): S172, September, 2000

Palliative treatment by high-dose-rate intraluminal brachytherapy in patients with advanced esophageal cancer. BrachyTherapy 3(2): 87-94, 2004

A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. RadioTherapy and Oncology 121(2): 299-303, 2016

Palliative treatment of esophageal cancer with dysphagia: more favourable outcome from single-dose internal brachytherapy than from the placement of a self-expanding stent; a multicenter randomised study. Nederlands Tijdschrift Voor Geneeskunde 149(50): 2800-2806, 2006

Complete pathologic remission after preoperative high-dose brachytherapy in patients with operable cervical cancer: preliminary results of a prospective randomized study. Magyar Onkologia 56(3): 171-177, 2013

EP-1949: Palliative combined treatment by high-dose-rate brachytherapy and stents in patients with esophageal cancer. RadioTherapy and Oncology 111: S339-S340, 2014

Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. International Journal of Radiation Oncology, Biology, Physics 76(3): 809-815, 2010

Comparison of efficacy and safety of low-dose-rate vs. high-dose-rate intraluminal brachytherapy boost in patients with superficial esophageal cancer. BrachyTherapy 11(2): 130-136, 2012